Abstract Aim of the work: To evaluate the incidence, clinical associations and outcome of APS nephropathy in SLE patients with 2ry APS.
Introduction
Antiphospholipid antibodies (aPL) are a heterogeneous group of antibodies directed against negatively-charged phospholipids, phospholipid-binding proteins, and phospholipid-protein complexes. The laboratory investigations of the update criteria for definite antiphospholipid syndrome (APS) includes the lupus anticoagulant (LAC), the anticardiolipin antibody (aCL), and the anti-b2 glycoprotein I (b2GPI) antibody [1] .
Conley and Hartman initially described the presence of lupus anticoagulants in SLE patients in 1952 [2] . Subsequently, Bowie and his colleagues described thrombosis occurring in patients with circulating anticoagulants in a seminal paper in 1963 [3] . These observations of the association of APA with glomerular and arterial thrombosis in SLE were extended over the next two decades by Kant and his associates, who reported a strong association between the presence of lupus anticoagulants and the presence of glomerular thrombi in renal biopsy specimens systematically performed in SLE patients seropositive for lupus anticoagulant [4] . While the precise origin of APAs in SLE was unclear, their presence appears to consistently correlate with the occurrence of renal thrombotic microangiopathy (TMA).
In the course of the antiphospholipid syndrome (APS), the existence of vaso-occlusive lesions capable of affecting numerous organs is now well established. The renal involvement attributable to APS nephropathy (APSN), corresponds to vaso-occlusive lesions of the intrarenal vessels, associating side-by-side with acute thromboses (with chronic arterial and arteriolar lesions) leading to zones of cortical ischemic atrophy [5] .
The renal involvement had been associated with both primary and secondary APS. Clinical features include hypertension, renal artery stenosis, thrombotic microangiopathy and other histological manifestations of the nephropathy (APSN), renal vein thrombosis, APSN in the course of systemic lupus erythematosus and renal failure. APSN is an independent risk factor that should be included in the classification criteria for definite APS with characteristic clinical and histological features [6] .
Patients and methods

Patients
Sixty-four female SLE patients fulfilling the updated American College of Rheumatology (ACR) revised criteria for the classification of SLE [7] were consecutively recruited from Rheumatology department, Cairo and Fayoum University hospitals. All of them have nephritis and thirty-two of them have secondary antiphospholipid syndrome. APS was diagnosed according to the Sapporo criteria [8] . Patients are classified into two groups: (group 1) SLE patients with 2ry APS and (group 2) SLE patients without APS. In (group 1) 15/32(46.9%) had recurrent fetal loss, 4/32 (12.5%) had CVA, one patient (3.1%) had Pulmonary artery embolism, also one patient had transverse myelitis (3.1%) and finally 17/32(53.1%) had venous thrombosis. Full history taking, thorough clinical examination and laboratory investigations were done. Assessment of disease activity was performed using the systemic lupus erythematosus disease activity index (SLEDAI) [9] , disease damage using the Systemic Lupus International Collaboration Clinics/ACR damage index (SLICC/DI) [10] . Renal biopsy was done to all patients, the specimens processed for light microscopy and classified according to the 1982 modified WHO morphologic classification of lupus nephritis [11] . Informed consents were taken from the patients and the study was approved by the local ethics committee.
Renal biopsy
The kidney biopsy was performed in all patients who had either proteinuria (urinary protein concentration P 500 mg/ dl), abnormal urinary sediment, or an elevated serum creatinine level. The biopsy specimens had been studied, using light and immunofluorescence microscopy, by renal pathologist who had no knowledge of the clinical and laboratory features of the patients. The World Health Organization (WHO) classification of lupus glomerulonephritis [11] and the WHO activity and chronicity index scores [12] were reevaluated.
The immunofluorescence microscopy findings as described in the initial reports of the kidney biopsies were accepted. APS nephropathy was diagnosed when at least 1 of the following lesions was detected: thrombotic microangiopathy (TMA), characterized by the presence of fibrin thrombi in arterioles and/or glomeruli (acute lesion), or myofibroblastic intimal cellular proliferation leading to intimal thickening of interlobular arteries, organized thrombi with or without recanalization, fibrous arterial and arteriolar occlusion, and subcapsular zone with FCA (chronic lesions) [5] .
Laboratory investigations
Antinuclear and anti-DNA antibodies, C3, and C4 were assessed according to standard methods. Determination of IgG and IgM antibodies to aCL was performed with an enzymelinked immunosorbent assay [13] , Cardiolipin (50 lg/ml) in ethanol (Sigma, St. Louis, MO) was used as antigen on polystyrene micro titer plates (Nunc, Naperville, IL), which were left to dry overnight at 4°C. After washing with phosphate buffered saline, the nonspecific binding sites were blocked by 10% bovine serum in phosphate buffered saline. LAC was assayed by activated thromboplastin time [14] . The detection of LAC in medium or high titers of aCL at least 2 times, 6 weeks apart, before or at the time of kidney biopsy, was required [8] .
Exclusion criteria
The criteria for exclusion from the study were other potential causes for renal microangiopathy, such as systemic sclerosis, malignant hypertension, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, postpartum renal failure, preeclampsia, diabetic nephropathy, chemotherapy, or cyclosporine therapy.
Radiological examination 2.5.1. Renal ultrasound and color Doppler examination
Renal Doppler US was performed successfully in each study patient and was accomplished in 15 min or less. In each patient, both kidneys were examined with real-time US, performed with a 3.5-5 MHz transducer.
Assessment of the size, parenchymal thickness and cortical contour of both kidneys were performed. The echogenicity and cortico-medullary differentiation of the kidneys were assessed.
The intra-renal arteries were examined with pulsed Doppler US at the same respective scanning frequencies. Multiple Doppler signal tracings and a standard gray-scale examination of the kidney were recorded. Doppler signals were, in general, obtained from arcuate arteries at the cortico-medullary junction, interlobar arteries along the border of medullary pyramids, or both. The Doppler waveforms were made on the lowest pulse repetition frequency possible without aliasing. This maximized the size of the Doppler spectrum and decreased the percentage of error in the measurements. In addition, the lowest possible wall filter for each US scanner was used. Doppler sample width was set at 2-5 mm. The resistive index (RI) ([peak systolic frequency shift-minimum diastolic frequency shift]/peak systolic frequency shift) was calculated. The RI for each kidney was calculated as an average value obtained from three to five waveforms recorded in three different regions of the kidney. An RI of P0.70 was considered abnormal.
The main renal arteries were also examined for focal areas of stenosis or luminal reduction. Multiple Doppler tracings were recorded for elevated peak systolic velocity (PSV) or RI [15] .
Magnetic resonance angiography of both renal arteries
All MR angiography examinations were performed by using a 1.5-T whole-body MR system (Philips Medical Systems) with a gradient strength of 30 mT/m and a slew rate of 150 (mT-m-1)/ msec. A four-element phased-array body coil was used for signal reception.
Coronal single-shot fast SE or half-Fourier single-shot turbo SE imaging with the following parameters: repetition time (msec)/echo time (msec), 1/120; flip angle. 90°; and acquisition time, 20 s (breath hold). This heavily T2-weighted sequence provides an overview of the upper abdominal anatomy, renal parenchyma and collecting system and serves as a localizing sequence for planning other sequences in the protocol.
Furthermore, a two-dimensional non enhanced phasecontrast (PC) sequence (5/3 and 50°flip angle) was performed followed by standard time of flight (TOP) sequence (4.2/1.8 and 70°flip angle) [16] .
99mTc-DMSA (
99m Tc-dimercaptosuccinic) scan acquisition and interpretation DMSA scan was performed using a standard protocol. Injected activities were the recommended adult dose in the range of 3-5 mCi (110 MBq-185 MBq). Data were acquired on a dual-head, large-field-of-view gamma camera (AxisPhillips-Marconi medical systems) equipped with low-energy, high-resolution parallel collimators in a 256 · 256 matrix. Planar posterior, anterior, left posterior, and right posterior oblique views were obtained 3-4 h after intravenous injection of 99m Tc-DMSA (Renocis; CIS Bio International, Gif-sur-Yvette, France). Acquisitions were continued to a total of 750 kilocounts or 300 s (5 min). No sedation was used [17, 18] .
Two experienced physicians unaware of the patient's clinical and radiological data interpreted the findings according to the criteria of Patel and his colleagues as shown in (Table  1 ) and discrepancies were resolved by consensus. At the time of diagnosis, DMSA findings were judged to be abnormal when the criteria for scarring were satisfied. Defects located centrally over the pelvicalyceal system were not considered abnormal [19] .
Statistical analysis: The data were coded and entered using the statistical package SPSS version 15. The data were summarized using descriptive statistics: mean, standard deviation, minimal and maximum values for quantitative variables and number and percentage for qualitative values.
Statistical differences between groups were tested using Chi Square test for qualitative variables, independent sample t test for quantitative normally distributed variables while Nonparametric Mann Whitney test was used for quantitative variables which are not normally distributed. P-values less than or equal to 0.05 were considered statistically significant [20] . Table 2 , laboratory parameters and renal biopsy of the two groups are presented in Table 3 and medication received are presented in Table 4 .
Results of magnetic resonance angiography of both renal arteries
MR angiography had detected 7(21.9%) patients with RAS in (group1) and on comparing the two groups it showed a statistically highly significant difference (p = 0.005). RAS appeared as smooth, well-defined and noncritical stenosis distal to the renal artery ostium as shown in (Fig. 1) . Patients with RAS showed a significant association with TMA and proteinuria (p = 0.002 and p = 0.004, respectively). Patients with RAS had higher DBP, s.creatinine, TGs and renal RI than those without RAS (p = 0.004, p = 0.005, p = 0.003 and p = 0.008, respectively). MR angiography also detected 5(15.6%) patients with renal artery thrombosis in (group1) as shown in (Fig. 1) that showed a statistically significant difference (p0.02) on comparing the two groups. Patients with renal artery thrombosis showed a significant association with TMA, proteinuria and arthritis (p < 0.001, p = 0.02 and p = 0.03, respectively). Patients with renal artery thrombosis had higher SBP, DBP, thrombocytopenia, s.creatinine, TGs and renal RI (p = 0.004, p = 0.000, p = 0.04, p = 0.0004, p = 0.009 and p = 0.04, respectively).
Results of 99m Tc-DMSA scan
Renal DMSA scan had detected 6(18.8%) patients with cortical scar as shown in (Fig. 2) which showed a statistically significant difference (p = 0.02) on comparing the two groups. It showed also a significant association with TMA (p = 0.001) and significant association with proteinuria, livedoreticularis and arthritis (p = 0.01, p = 0.04 and p = 0.03, respectively). Patients with cortical scar had higher DBP and renal RI (p = 0.000 and p = 0.006, respectively).
Results of renal ultrasound and color Doppler examination
Renal Duplex detected 12(37.5%) patients with increased echogenecity (nephropathy) which showed a significant association with alopecia, fever, TMA, proteinuria, casturia and mucosal ulcers (p < 0.001, p = 0.02, p = 0.005, p = 0.004, p = 0.02 and p = 0.01, respectively). Patients with › ecchogenecity had higher DBP, renal RI and ESR (p = 0.02, p = 0.000 and p = 0.01, respectively). Decreased renal size had been detected by renal Duplex in one patient only (3.1%) and showed a significant association with TMA (p = 0.02).
Discussion
The antiphospholipid antibody syndrome (APS) described a clinical entity with recurrent thrombosis, fetal loss, thrombocytopenia in the presence of lupus anticoagulant and/or antibodies to cardiolipin. These antibodies may be associated with connective tissue diseases such as systemic lupus erythe- matosus (secondary APS) or be found in isolation (primary APS). Renal syndromes increasingly being reported in association with these antibodies which include thrombotic microangiopathy, renal vein thrombosis and renal infarction, renal artery stenosis [21] .
In the current study we had found that aPL antibodies in SLE patients with renal involvement represent a strong risk factor for the RAS and the thrombotic events within the kidney.
In the present study we had examined 64 SLE patients with nephritis, 50% of them had 2ry APS, to detect renal manifestations caused by aPL antibodies by different means as renal Duplex, renal MRA and renal DMSA scan.
MR angiography detected 7/32(21.9%) patients with RAS, who showed highly significant association with hypertension and this can be explained by the fact that RAS impairs renal perfusion, leading to renal ischemia, which in turn activates the rennin-angiotensin axis. The production of angiotensin II leads to sodium retention, vasoconstriction and increased sympathetic activity. It also has detrimental effects on nitric oxide production and endothelial function. Renovascular hypertension is the result of this process [22, 23] .
TMA were present in 6/32(18.8%) patients with 2ry APS and had a highly significant association with renal infarctions that had been detected by DMSA scan as micro thrombi could mechanically obstruct glomerular capillaries, diminishing the blood supply to glomeruli and renal tubules, thereby causing chronic hypoxic/ischemic injuries to the affected glomeruli and tubules. This would in turn decrease the glomerular filtration rate leading to the loss of nephrons and impaired renal function. Clinical studies had indicated that lupus nephritis (LN) patients with glomerular micro thrombi (GMT) had more severe renal tissue injury, poorer response to general treatment and worse renal outcome than patients without GMT [5] . Consistent with these findings, we had demonstrated in the present study that LN patients with GMT had higher damage index (SLICC) than those without. The level of serum creatinine, and proteinuria, as well as the frequency of systemic hypertension, were all significantly greater in patients with GMT. Taken together, GMT may be an important cause of renal injury and renal dysfunction in a subset of patients with LN and this coincides with the results of Hui Zheng and his colleagues [24] and also with those of Imad Uthman and Munther Khamashta who documented that. The development of aPL nephropathy in the context of SLE nephritis increases the risk of a poor renal outcome [25] .
Antiphospholipid syndrome nephropathy had been described as a distinct entity found in one third of lupus nephritis patients but independent of the lupus lesions [26] . In the present study APS nephropathy had been detected in (21.9%) of our patients which was a little bit lower than the described percentage and this can be explained by the lower number of SLE patients with 2ry APS taken in the present study, which should be increased in future studies.
APS nephropathy was strongly associated with both aCL and LA, suggesting that APL plays a direct role in the development of APS nephropathy [27] and this also coincides with the results of the present study.
Low density lipoproteins were significantly lower in cases with SLE and 2ry APS, this can be explained by being consumed. This was previously explained by Hasunuma Y. and his colleagues who documented at a molecular level, that anticardiolipin antibodies (aCL) had been shown to have atherogenic properties. For example, aCL can cross react with oxidized low density lipoproteins (ox-LDL), and may enhance the in vitro uptake of ox-LDL by monocytes [28] .
Sangle and his colleagues had demonstrated the presence of RAS in (26%) of (77) patients with aPL and uncontrolled blood pressure (60 with SLE and APS, 11 with primary APS, 6 with aPL only). They observed two possible patterns regarding stenotic artery lesions. The most represented pattern was smooth, well-defined and noncritical stenosis distal to the renal artery ostium, these findings are different from atherosclerotic and fibromuscular dysplasia-related lesions. Indeed, the other described pattern seems to be similar to atherosclerotic lesions and had been found in the proximal region to the ostium of the renal artery, sometimes involving the aorta [29] . This coincides with the results in the present study as we found RAS in (21.9%) of patients and they appeared as smooth, well-defined and noncritical stenosis distal to the renal artery ostium, but we did not find proximal lesions.
Conclusion
Previously, it was said that, in SLE patients with aPL it is crucial to distinguish between renal failure due to SLE nephritis (immune-complex disease) from that due to APS (glomerular thrombosis). This distinction, which can only be accomplished by kidney biopsy, is critical as the treatment for each syndrome is different. Aggressive SLE nephritis requires cytotoxic therapy, whereas APS nephropathy benefits from anticoagulation. But now we can add that renal MR angiography and renal DMSA can differentiate between the two conditions, which are less aggressive and safer maneuvers than renal biopsy especially in patients with thrombocytopenia accompanying APS.
